Under the general trend of pharmaceutical reform, the personnel changes of pharmaceutical company executives will become more and more frequent

Recently, the transfer of senior management in the pharmaceutical industry has been relatively frequent, and the directors, deputy general managers, and supervisors of many listed companies have begun to change one after another, including Hengrui, Northeast Pharmaceutical, and Kangchen Pharmaceutical
.
The new vice president of Hengrui has been selected.
Recently, Dr.
Joseph E.
Eid, an expert in the field of medicine, officially announced that he will join Hengrui Medicine in October as executive vice president, chief medical officer and head of global drug development; its future will focus on the United States and Europe.
Drug development affairs in the market
.
It is reported that as a medical oncologist and hematologist, Dr.
Joseph E.
Eid has more than 20 years of rich experience in clinical development and medical affairs in academic medicine and biopharmaceutical industries, covering small molecules, monoclonal antibodies and immuno-oncology Clinical Phase 1-4 projects also have regulatory expertise including IND, BLA and NDA
.
It is worth noting that Dr.
Joseph E.
Eid has also held senior management positions in many multinational pharmaceutical companies such as Roche, Merck & Co.
, Bristol-Myers Squibb
.
In this regard, the industry believes that the appointment of Dr.
Josehf E.
Eid will be a manifestation of Hengrui Medicine’s acceleration of its internationalization process
.
The new chairman of Northeast Pharmaceutical took office On October 8, Northeast Pharmaceutical issued an announcement stating that the company held the 58th meeting of the eighth board of directors on October 3, and the meeting reviewed and approved the company’s director Mr.
Guo Jianmin as chairman
.
It is understood that in fact, many senior executives of Northeast Pharmaceutical have resigned this year
.
Guo Qiyong, the former chairman of Northeast Pharmaceutical, resigned on September 28, less than a year after he took office; on June 29, Xu Zhixin applied to resign as a director of the eighth board of directors of Northeast Pharmaceutical due to personal job changes; April On the 27th, Deputy General Manager Yang Wenfeng resigned due to job adjustments; on February 22, Chief Financial Officer Ma Zhuo resigned due to job changes
.
Employee Supervisor of 3SBio Group resigns on October 11, 3SBio Group issued an announcement stating that on September 30, 2021, the company’s board of supervisors received a written resignation report from Ms.
Jiang Lili, employee representative supervisor of the 4th Board of Supervisors
.
Ms.
Jiang Lili applied to resign from the position of employee representative supervisor of the 4th Board of Supervisors of the company due to personal reasons
.
At present, in order to improve the corporate governance structure and ensure the standard operation of the company's board of supervisors, the company has held a staff representative meeting on September 30, 2021, and elected Ms.
Wu Jing as the employee representative supervisor of the company's fourth board of supervisors
.
Many senior executives of Yuandong Biotechnology have personnel changes.
On October 12, Yuandong Biotechnology issued an announcement that many senior executives of the company had personnel changes
.
Among them, Wang Wuping resigned from the post of secretary of the board of directors due to personal reasons, and his resignation time is October 11, 2021
.
At the same time, Wang Yiou assumed the position of secretary of the board of directors, taking office on October 11, 2021
.
Conclusion In general, judging from the content of the major announcements, there are both newly appointed executives and resigned executives, and the changed executives are mostly concentrated in general manager, deputy general manager, director and other positions.
The reasons for the change it includes personal reasons, health reasons, job transfers and so on
.
In this regard, industry analysts believe that the domestic pharmaceutical industry is undergoing drastic changes, and the continuous adjustment of senior management of pharmaceutical companies is an inevitable trend under such changes
.
It is expected that such frequent personnel changes in the pharmaceutical industry will continue to occur in the future under the general background of medical reform
.